Guelder Rose (Viburnum opulus) Industrial Sourcing Brief 2026 H2 — Carpathian Wildcraft Reality, Analytical Spec Discipline, and Why There Is No EMA Monograph Yet

Procurement teams sourcing guelder rose (Viburnum opulus) into Europe in 2026 are working with one of the most documented-yet-fragmented niche botanicals in the EU-East frontier supply pool. There is no EMA HMPC monograph for Viburnum opulus — the [EMA herbal monograph register](https://www.ema.europa.eu/en/human-regulatory-overview/herbal-medicinal-products/european-union-monographs-list-entries) lists no entry for the species. There are documented parallel ethnobotanical traditions in Slavic Europe (kalyna) and inner Anatolia (gılaburu), but the "shared tradition" framing common in marketing copy is two independent parallel uses, not a peer-reviewed common origin. The "post-frost chemistry transformation" narrative that travels through gardening blogs is extrapolated from American Viburnum trilobum literature — peer-reviewed work on V. opulus does not document a measured pre-frost-to-post-frost compositional shift. This brief is the honest industrial sourcing reference for guelder rose: what's actually in the European Pharmacopoeia, what isn't in the EMA monograph register, what the peer-reviewed phytochemistry actually says, and where the documented Carpathian wildcraft supply sits relative to Turkish cultivated production.

The taxonomy nobody on the buyer side wants to relitigate but should

What the cosmetic and supplement market labels "Viburnum opulus" is, on inspection, two related taxa with overlapping but allopatric distributions. Viburnum opulus var. opulus is the Eurasian taxon — Romanian Carpathian, Ukrainian Bukovina, Polish, Hungarian, Turkish Anatolian. The North American Viburnum opulus var. americanum (the former Viburnum trilobum) is the parallel taxon native to the United States and Canada ([Oregon State Landscape Plants — V. opulus var. opulus / var. americanum](https://landscapeplants.oregonstate.edu/viburnum-opulus-var-opulus-and-viburnum-opulus-var-americanum)). The two are morphologically similar; commercial confusion at the nursery and ingredient-supply level is documented enough that a specification that needs the Eurasian taxon should write the variety into the contract rather than rely on the species name. The Turkish flora documents four Viburnum species in the country — V. opulus L., V. orientale Pallas, V. lantana L., V. tinus L. — with V. opulus the only commercially relevant one for the gılaburu trade.

A second taxonomy item worth flagging: most of the older Viburnum bark pharmacopoeia literature (Cramp Bark) cites a compound called "viburnin" as the bitter principle. The British Herbal Pharmacopoeia and the American Herbal Pharmacopoeia both reference it; the modern phytochemistry literature has not fully characterised viburnin as a single defined molecule — it appears to be a category label inherited from eclectic-medicine literature (Felter, 1922) rather than a contemporary HPLC-identifiable compound ([Drugs.com NPP — Cramp Bark](https://www.drugs.com/npp/cramp-bark.html); [Henriette's Herbal — Felter eclectic monograph](https://www.henriettes-herb.com/eclectic/felter/viburnum-opul.html)). The bitter chemistry that is contemporarily characterised is valeric/valerianic acid + tannins (~3%) + saponins + coumarins (scopoletin/scopolin) + arbutin in the bark, with the berry running on a separate compound profile.

Berry phytochemistry — peer-reviewed ranges

The most-cited peer-reviewed review on Viburnum opulus chemistry is the 2020 [Nutrients review by Kajszczak et al.](https://pmc.ncbi.nlm.nih.gov/articles/PMC7694363/), which catalogues the berry as containing phenolic compounds, vitamin C, carotenoids, iridoids, and essential oils, with sensory profile bitter + astringent + sour. Vitamin C content varies widely by cultivar and ecotype: 12.4 to 164.0 mg/100 g fresh weight across the published range, with most commercial cultivars sitting in the 28–43 mg/100 g medium-level band. Anthocyanin content in the juice runs 24.3 to 51.3 mg cyanidin-3-glucoside equivalents per 100 g. The 'Krasnaya Grozd' cultivar — used as a high-end reference in eastern European cultivar trials — reaches 1,168 mg/100 g total phenolics. Juice pH lands at 2.6–3.7; soluble solids at 7.5–11.6 °Brix ([BioResources 2026 morphological and biochemical diversity study](https://bioresources.cnr.ncsu.edu/wp-content/uploads/2026/01/BioRes_21_1_1529_Alan_Morph_Biochem_Diversity_Viburnum_Genotypes_25358.pdf); [PMC6268750 anthocyanin degradation kinetics](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6268750/)).

What's worth pointing out is what the peer-reviewed literature does not document. The "post-frost preferred" harvest practice — well-established in gardening literature and in folk-medicine traditions — is reported as a sensory and practical observation (bitterness decreases, sugar perception increases) rather than as a measured peer-reviewed compositional shift on V. opulus specifically. The "frost-improved" compositional change is documented for V. trilobum (American cranberrybush) but has not been characterised on V. opulus with the same analytical depth. A buyer's procurement specification that depends on "post-frost chemistry" is therefore depending on a traditional posture rather than a published peer-reviewed mechanism. The defensible procurement anchor for V. opulus berry product is HPLC-quantified anthocyanin floor + vitamin C floor + total phenolic floor + the standard regulatory contaminant panel, with the harvest-window framing (post-frost preferred) as a sensory-quality flag rather than as a chemistry warranty.

Safety — the LD50 number that the supplement-dose discussion needs

Safety data on V. opulus extract is documented at peer-reviewed level. The [2023 ScienceDirect safety assessment of V. opulus juice](https://www.sciencedirect.com/science/article/abs/pii/S0278691523004842) and the [PMC8182012 acute and subacute oral toxicity study](https://pmc.ncbi.nlm.nih.gov/articles/PMC8182012/) on Sprague-Dawley rats place the acute oral LD50 above 2,000 mg/kg — the standard "non-toxic at acute single-dose" threshold. The 28-day subacute study at 2,000 mg/kg/day produced documented kidney + liver + adipose-tissue toxicity markers and elevated platelet counts; the 500 mg/kg/day dose was the documented safe level in the same study. The procurement-side implication is that traditional juice consumption doses are well inside the safe envelope, but supplement-grade concentrated extract dosing needs the safety-margin discussion built into the dossier — a 4× ratio between the documented safe dose and the documented adverse-effect dose is a relatively narrow therapeutic window for a botanical, and supplement-product positioning that doesn't disclose that ratio is operating under-informed.

The marketing claim "EMA-approved for kidney stones" appears in some supplement copy and is not supported by the regulatory record. There is no EMA HMPC monograph for V. opulus. There is one small Turkish clinical study on distal ureteral stones ([PMC7595025](https://pmc.ncbi.nlm.nih.gov/articles/PMC7595025/)) and a rat-model study on calcium oxalate stone formation ([PMC4137613](https://pmc.ncbi.nlm.nih.gov/articles/PMC4137613/)) — both promising preliminary work, but neither equivalent to an EMA-authorised therapeutic claim. A downstream product positioning that names "EMA-approved" is overstating the regulatory case.

EU regulatory status — what the framework actually says

The negative regulatory finding for V. opulus is itself the headline: there is no EMA HMPC monograph, neither traditional-use nor well-established-use. The species sits outside the EU-central herbal monograph register. The British Herbal Pharmacopoeia (BHP) and the American Herbal Pharmacopoeia (AHP) do carry Cramp Bark (the dried bark of V. opulus / V. prunifolium), but those are not EU-binding pharmacopoeial standards. The European Pharmacopoeia does not carry a Viburnum opulus monograph at the time of writing.

On the cosmetic side, the Cosmetic Regulation 1223/2009 INCI / CosIng position is well-defined. The following INCI names are registered: VIBURNUM OPULUS BARK EXTRACT (EINECS 290-415-5, CAS 90131-98-9, function: astringent + skin conditioning), VIBURNUM OPULUS EXTRACT, and VIBURNUM OPULUS FRUIT EXTRACT ([INCI Beauty entry](https://incibeauty.com/en/ingredients/18341-viburnum-opulus-bark-extract); [COSMILE Europe INCI](https://cosmileeurope.eu/inci/detail/16856/viburnum-opulus-bark-extract/)). INCI listing is nomenclature-only and does not constitute a functional regulatory claim.

On the EU Novel Food position, the conservative buyer posture is to verify the EC Novel Food catalogue entry for the specific preparation form before commercial commitment. The documented food consumption history of V. opulus in Slavic Europe and inner Anatolia predates May 1997, which is the conventional cutoff for "history of consumption" exclusion from Novel Food review — gılaburu juice in Turkish folk medicine and sok kalina in Polish / Ukrainian / Russian tradition are both pre-1997 documented uses. The pragmatic procurement framing is that V. opulus berry traditional preparations are likely outside Novel Food scope, but novel extracts (supercritical CO₂ concentrates, isolated iridoid fractions, standardised polyphenol preparations) may trigger Novel Food review depending on the preparation route. The buyer's QA team should confirm the EC Novel Food catalogue entry for the exact preparation form.

The EFSA Article 13 health claim register does not surface a specific authorised V. opulus claim; any related on-hold botanical claim is in the same Reg 1924/2006 Article 28(5) transitional limbo as the hawthorn, aronia, sea-buckthorn, and rosehip claims discussed in our other sourcing guides. The downstream positioning of any V. opulus product needs to handle this carefully.

Forms, grades, and the per-shipment compliance panel

The commercial V. opulus supply chain runs on three primary forms: dried whole berries (post-frost harvest, traditional preferred form for tea + tincture preparations), juice concentrate (the gılaburu suyu commercial format in Turkey, sok kalina in Slavic Europe), and dried bark (Crampbark, the UK + US phytotherapy bark line). The per-shipment compliance panel follows the standard botanical framework: heavy-metal panel per Regulation (EU) 2023/915 (Pb, Cd, Hg, As, Ni, category-specific maximum levels — no V. opulus carve-out); pesticide multi-residue panel per Regulation (EC) 396/2005 (default 0.01 mg/kg if no species-specific MRL); microbiological panel per Regulation (EC) 2073/2005 for processed product chains. Public wholesale tier pricing for V. opulus is not well-documented in the conventional B2B aggregators — the search-cost for procurement teams is genuinely higher for this category than for aronia or hawthorn, which is part of what a broker positioning can address.

Source geographies — Carpathian wildcraft and the Turkish cultivated divergence

The documented V. opulus supply geographies sit in three distinct postures. Ukrainian wild-harvest — particularly the Carpathian Bukovina cross-border zone documented in [the Pieroni et al. ethnobotanical Carpathian work](https://www.academia.edu/41885791/Botanical_Provenance_of_Traditional_Medicines_From_Carpathian_Mountains_at_the_Ukrainian_Polish_Border) — is the active commercial wildcraft supply, with kalyna dried-berry export flow into retail and small-volume B2B channels. Romanian Carpathian wild collection is present in the same ethnobotanical literature but does not have a consolidated dedicated commercial wildcraft volume figure in public trade data — the Tandor Suceava broker positioning sits at the geographical centre of this gap, which is both a market position and a procurement-volume frontier rather than a documented industrial supply base.

Turkish production, by contrast, is cultivated, not wild. The principal production sits in Kayseri province — specifically Akkışla and Bünyan districts, with approximately 65% of national production concentrated in Akkışla according to the [ORAN Kayseri Investment Guide (2018)](https://www.oran.org.tr/images/dosyalar/20180803153634_1.pdf). Gılaburu carries Geographical Indication (GI) registration. The 2021 harvest reported approximately 50% yield loss against historical averages, with the [Tridge GI commentary](https://www.tridge.com/news/geographical-indication-registered-low-yield-in-gi) documenting the supply pressure. The Turkish cultivated supply runs primarily into the juice concentrate channel; the dried-berry channel sits more on the Ukrainian + Romanian wildcraft side.

2026 H2 procurement timing and the Carpathian frontier posture

The V. opulus harvest window runs from the late summer berry ripening through the post-frost preferred picking window in October–November, depending on the specific Carpathian first-frost timing each year. Public industry forecasting for the 2026 H2 V. opulus harvest is not available at the granularity that buyers have access to for Polish aronia or Bulgarian rosehip — V. opulus sits in the commercially-fragmented frontier category where the procurement search cost is genuinely higher and the broker value proposition is correspondingly clearer.

Tandor is an EU-organic botanical sourcing broker based in Suceava, Romania — literally the southern edge of the Bukovina ethnobotanical region documented in the Carpathian wildcraft literature. For a 2026 H2 V. opulus procurement engagement the brief covers form (dried whole berries / juice concentrate / dried bark), preparation specification (HPLC anthocyanin floor + vitamin C floor + total phenolic floor for the berry line; CIR safety panel for cosmetic-grade bark extract), volume, EU-Organic operator certificate identifier where applicable, EU Novel Food catalogue verification for the specific preparation form, EU Reg. 2023/915 heavy-metal COA, pesticide residue panel under Reg. 396/2005, microbiological panel under Reg. 2073/2005, delivery point and Incoterm.

Tandor returns multi-supplier comparisons with verified analytical specifications, sample dispatch coordination, COA collection per shipment, and DDP delivery support. Tandor is currently in pre-launch — sourcing intros, RFQ qualification, sample dispatch coordination, and DDP logistics are all free during this phase. Transparent commercial terms publish with the formal commercial offering opening later this year.

For Q3 and Q4 2026 V. opulus procurement the cleanest starting point is a written buyer brief sent to info@tandor.eu. The honest guelder rose sourcing position is straightforward: there is no EMA monograph, no consolidated EU-central pharmacopoeial standard, no Cochrane-grade clinical evidence base for the cardiovascular or kidney-stone marketing claims that circulate in supplement copy. What there is: documented peer-reviewed phytochemistry, a well-characterised safety envelope with a 4× ratio between documented safe and adverse-effect doses, a real Carpathian wildcraft supply base in Ukrainian Bukovina and adjacent Romanian collection territory, a Turkish cultivated supply running into the juice concentrate channel, and a regulatory framework that the buyer's QA team should run through the Novel Food catalogue per preparation form before commercial commitment. That is the analytical-spec discipline and the regulatory honesty that gets reliable allocation through a fragmented frontier-category procurement cycle.

---

*This brief draws on Kajszczak et al. (Nutrients 2020 review of V. opulus phytochemistry), the BioResources 2026 morphological and biochemical diversity study, PMC6268750 anthocyanin degradation kinetics, the 2023 ScienceDirect safety assessment of V. opulus juice, PMC8182012 acute and subacute oral toxicity study, the EMA herbal monograph register (negative finding — no V. opulus entry), the European Pharmacopoeia, the British Herbal Pharmacopoeia and American Herbal Pharmacopoeia Cramp Bark monographs (non-EU), Drugs.com Natural Products Database, Oregon State Landscape Plants for V. opulus var. opulus / var. americanum taxonomy, the Pieroni et al. Carpathian Bukovina cross-border ethnobotanical work, the ORAN Kayseri Investment Guide (2018) for Turkish cultivated production data, the Tridge GI commentary on the 2021 yield loss, the COSMILE Europe and INCI Beauty registers for cosmetic INCI status, EUR-Lex (Regulations 2023/915 + 396/2005 + 2073/2005 + 1924/2006 + 1223/2009), and PMC7595025 + PMC4137613 preliminary clinical and rat-model kidney-stone studies. Marketing claims of "EMA-approved kidney stone treatment", "post-frost chemistry transformation documented at peer-reviewed level for V. opulus specifically", "shared Slavic-Anatolian heritage tradition", and "cyanogenic glycoside detox via frost" are not supported by the cited peer-reviewed and regulatory sources and have been deliberately excluded. Where documented food consumption history pre-dates May 1997 the conservative procurement framing is that traditional V. opulus berry preparations likely fall outside EU Novel Food scope, but the buyer's QA team should verify the EC Novel Food catalogue entry for the specific preparation form before commercial commitment.*